

1. Record Nr.	UNINA990003773810403321
Autore	Lévi-Strauss, Claude <1908-2009>
Titolo	Parole date : le lezioni al Collège de France e all'Ecole pratique des hautes études (1951-1982) / Claude Lévi-Strauss ; traduzione di Giuseppe Mongelli
Pubbl/distr/stampa	Torino : Einaudi, ©1992
ISBN	88-06-12636-9
Descrizione fisica	vi, 276 p. ; 21 cm
Collana	Einaudi Paperbacks. Antropologia ; 221
Disciplina	306.08 306.01
Locazione	BFS
Collocazione	306.01 LVS 6
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Trad. di Paroles Données

2. Record Nr.	UNINA9910877239103321
Autore	Poongavanam Vasanthanathan
Titolo	Computational Drug Discovery : Methods and Applications
Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2024 ©2024
ISBN	9783527840748 3527840745 9783527840724 3527840729 9783527840731 3527840737
Edizione	[1st ed.]
Descrizione fisica	1 online resource (739 pages)
Altri autori (Persone)	RamaswamyVijayan
Disciplina	615.190015118
Soggetti	Computational chemistry Molecular dynamics Quimioinformàtica Dinàmica molecular Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Title Page -- Copyright -- Contents -- Preface -- Acknowledgments -- About the Editors -- Part I Molecular Dynamics and Related Methods in Drug Discovery -- Chapter 1 Binding Free Energy Calculations in Drug Discovery -- 1.1 Introduction -- 1.1.1 Free Energy and Thermodynamic Cycles -- 1.2 Endpoint Methods -- 1.2.1 MM/PBSA and MM/GBSA -- 1.2.2 Linear Response Approximations -- 1.3 Alchemical Methods -- 1.3.1 Free Energy Perturbation -- 1.3.2 Thermodynamic Integration -- 1.3.3 Bennett's Acceptance Ratio -- 1.3.4 Nonequilibrium Methods -- 1.3.5 Multiple Compounds -- 1.3.6 OneStep Perturbation Approaches -- 1.3.7 Challenges in Alchemical Free Energy Calculations -- 1.4 Pathway Methods -- 1.5 Final Thoughts -- References -- Chapter 2 Gaussian Accelerated Molecular Dynamics in Drug Discovery -- 2.1 Introduction -- 2.2 Methods -- 2.2.1

Gaussian Accelerated Molecular Dynamics -- 2.2.2 Ligand Gaussian Accelerated Molecular Dynamics -- 2.2.3 Energetic Reweighting of GaMD for Free Energy Calculations -- 2.2.4 GLOW: A Workflow Integrating Gaussian Accelerated Molecular Dynamics and Deep Learning for Free Energy Profiling -- 2.2.5 Binding Kinetics Obtained from Reweighting of GaMD Simulations -- 2.2.6 Gaussian Accelerated Molecular Dynamics Implementations and Software -- 2.3 Applications -- 2.3.1 GProteinCoupled Receptors -- 2.3.1.1 Characterizing the Binding and Unbinding of Caffeine in Human Adenosine A2A Receptor -- 2.3.1.2 Unraveling the Allosteric Modulation of Human A1 Adenosine Receptor -- 2.3.1.3 Ensemble Based Virtual Screening of Allosteric Modulators of Human A1 Adenosine Receptor -- 2.3.2 Nucleic Acids -- 2.3.2.1 Exploring the Binding of Risdipam Splicing Drug Analog to SingleStranded RNA -- 2.3.2.2 Uncovering the Binding of RNA to a Musashi RNABinding Protein -- 2.3.3 Human Angiotensin Converting Enzyme 2 Receptor. 2.3.4 Discovery of Novel SmallMolecule Calcium Sensitizers for Cardiac Troponin C -- 2.3.5 Binding Kinetics Prediction from GaMD Simulations -- 2.4 Conclusions -- References -- Chapter 3 MD Simulations for DrugTarget (Un)binding Kinetics -- 3.1 Introduction -- 3.1.1 Preface -- 3.1.2 Motivation for Predicting (Un)binding Kinetics -- 3.1.3 The Time Scale Problem of MD Simulations -- 3.2 Theory of Molecular Kinetics Calculation -- 3.2.1 Nonequilibrium Statistical Mechanics in a Nutshell -- 3.2.2 Kramers Rate Theory -- 3.2.3 Biased MD Methods -- 3.2.3.1 Temperature and BarrierScaling -- 3.2.3.2 Bias PotentialBased Methods -- 3.2.3.3 Bias ForceBased Methods -- 3.2.3.4 Knowledge Biased Methods -- 3.2.3.5 Coarsegraining and Master Equation Approaches -- 3.3 Challenges and Caveats in Rate Prediction -- 3.3.1 Finding Reaction Coordinates and Pathways -- 3.3.2 Error Ranges of Estimates -- 3.3.3 A Need for Reliable Benchmarking Systems -- 3.3.4 Problems with Force Fields -- 3.4 Methods for Rate Prediction -- 3.4.1 Unbinding Rate Prediction -- 3.4.1.1 Empirical Predictions -- 3.4.1.2 Prediction of Absolute Unbinding Rates -- 3.4.2 Binding Rate Prediction -- 3.5 StateoftheArt in Understanding Kinetics -- 3.6 Conclusion -- References -- Chapter 4 Solvation Thermodynamics and its Applications in Drug Discovery -- 4.1 Introduction -- 4.1.1 Protein Folding -- 4.1.2 Protein-Ligand Interactions -- 4.2 Tools to Assess the Solvation Thermodynamics -- 4.2.1 Watermap -- 4.2.2 GIST -- 4.2.3 3DRISM -- 4.3 Case Studies -- 4.3.1 Watermap -- 4.3.1.1 Background and Approach -- 4.3.1.2 Results and Discussion -- 4.3.2 Grid Inhomogeneous Solvation Theory (GIST) -- 4.3.2.1 Objective and Approach -- 4.3.2.2 Results and Discussion -- 4.3.3 Three Dimensional Reference InteractionSite Model (3DRISM) -- 4.3.3.1 Objective and Background -- 4.3.3.2 Results and Discussion. 4.4 Conclusion -- References -- Chapter 5 SiteIdentification by Ligand Competitive Saturation as a Paradigm of Cosolvent MD Methods -- 5.1 Introduction -- 5.2 SILCS: Site Identification by Ligand Competitive Saturation -- 5.3 SILCS Case Studies: Bovine Serum Albumin and Pembrolizumab -- 5.3.1 SILCS Simulations -- 5.3.2 FragMap Construction -- 5.3.3 SILCSMC -- 5.3.4 SILCSHotspots -- 5.3.5 SILCS PPI -- 5.3.6 SILCSBiologics -- 5.4 Conclusion -- Conflict of Interest -- Acknowledgments -- References -- Part II Quantum Mechanics Application for Drug Discovery -- Chapter 6 QM/MM for Structure Based Drug Design: Techniques and Applications -- 6.1 Introduction -- 6.2 QM/MM Approaches -- 6.2.1 Combined Quantum Mechanical/Molecular Mechanical Energy Calculations -- 6.2.2 QM/MM Methods for the Evaluation of NonCovalent Inhibitor Binding -- 6.2.3 QM/MM Reaction Modeling -- 6.3 Applications of QM/MM for Covalent

Drug Design and Evaluation -- 6.3.1 Covalent Tyrosine Kinase Inhibitors for Cancer Treatment -- 6.3.2 Evaluation of Antibiotic Resistance Conferred by Lactamases -- 6.3.3 Covalent SARSCoV2 Inhibitors: Mechanism and Insights for Design -- 6.4 Conclusions and Outlook -- References -- Chapter 7 Recent Advances in Practical Quantum Mechanics and MixedQM/MMDriven XRay Crystallography and Cryogenic Electron Microscopy (CryoEM) and Their Impact on StructureBased Drug Discovery -- 7.1 Introduction -- 7.2 Feasibility of Routine and Fast QMDriven XRay Refinement -- 7.3 Metrics to Measure Improvement -- 7.3.1 Ligand Strain Energy -- 7.3.2 ZDD of Difference Density -- 7.3.3 Overall Crystallographic Structure Quality Metrics: MolProbity Score and Clashscore -- 7.4 QM Region Refinement -- 7.5 ONIOM Refinement -- 7.6 XModeScore: Distinguish Protomers, Tautomers, Flip States, and Docked Ligand Poses. 7.7 Impact of the QMDriven Refinement on Protein-Ligand Affinity Prediction -- 7.7.1 Impact of Structure Inspection and Modification -- 7.7.2 Impact of Selecting Protomer States: Implications of XModeScore on SBDD -- 7.8 Conclusion -- Acknowledgments -- References -- Chapter 8 QuantumChemical Analyses of Interactions for Biochemical Applications -- 8.1 Introduction -- 8.2 Introduction to FMO -- 8.3 Pair Energy Decomposition Analysis (PIEDA) -- 8.3.1 Formulation of PIEDA -- 8.3.2 Applications of PIEs and PIEDA -- 8.3.3 Example of PIEDA -- 8.4 Partition Analysis (PA) -- 8.4.1 Formulation of PA -- 8.4.2 Applications and an Example of PA -- 8.5 Partition Analysis of Vibrational Energy (PAVE) -- 8.5.1 Formulation of PAVE -- 8.5.2 Applications of PAVE -- 8.6 Subsystem Analysis (SA) -- 8.6.1 Formulation of SA -- 8.6.2 Examples of SA and PAVE -- 8.7 Fluctuation Analysis (FA) -- 8.8 Free Energy Decomposition Analysis (FEDA) -- 8.9 Other Analyses of Chemical Reactions -- 8.10 Conclusions -- References -- Part III Artificial Intelligence in Preclinical Drug Discovery -- Chapter 9 The Role of ComputerAided Drug Design in Drug Discovery -- 9.1 Introduction to Drug-Target Interactions, Hit Identification -- 9.2 Lead Identification and Optimization: QSAR and DockingBased Approaches -- 9.3 DTI Machine Learning Methods -- 9.4 Supervised, Nonsupervised and Semisupervised Learning Methods -- 9.5 GraphBased Methods to Label Data for DTI Prediction -- 9.6 The Importance of Explainable ML Methods: Linking Molecular Properties to Effects -- 9.7 Predicting Therapeutic Responses -- 9.8 ADMETtox Prediction -- 9.9 Challenging Aspects of Using Computational Methods in Drug Discovery -- 9.9.1 What are Those Limitations? -- References -- Chapter 10 AIBased Protein Structure Predictions and Their Implications in Drug Discovery -- 10.1 Introduction. 10.2 Impact of AIBased Protein Models in Structural Biology -- 10.2.1 Combination of AIBased Predictions with CryoEM and XRay Crystallography -- 10.2.2 Combination of AIBased Predictions with NMR Structures -- 10.2.3 Combination of AIBased Predictions with Other Experimental Restraints -- 10.2.4 Impact of Deep Learning Models in Other Areas of Structural Biology -- 10.3 Combination of AI Based Methods with Computational Approaches -- 10.3.1 Combination of Structure Prediction with Other Computational Approaches -- 10.4 Current Challenges and Opportunities -- 10.5 Conclusions -- References -- Chapter 11 Deep Learning for the StructureBased Binding Free Energy Prediction of Small Molecule Ligands -- 11.1 Introduction -- 11.2 Deep Learning Models for Reasoning About Protein-Ligand Complexes -- 11.2.1 Datasets -- 11.2.2 Convolutional Neural Networks -- 11.2.2.1 Background -- 11.2.2.2 Voxelized Grid Representation -- 11.2.2.3 Descriptors -- 11.2.2.4 Applications --

11.2.3 Graph Neural Networks -- 11.2.3.1 Background -- 11.2.3.2 Graph Representation -- 11.2.3.3 Descriptors -- 11.2.3.4 Applications -- 11.2.3.5 Extension to Attention Based Models -- 11.2.3.6 Geometric Deep Learning and Other Approaches -- 11.3 Deep Learning Approaches Around Molecular Dynamics Simulations -- 11.3.1 Enhanced Sampling -- 11.3.2 Physicsinspired Neural Networks -- 11.3.3 Modeling Dynamics -- 11.3.3.1 Applications -- 11.4 Modifying AlphaFold2 for Binding Affinity Prediction -- 11.4.1 Modifying AlphaFold2 Input Protein Database for Accurate Free Energy Predictions -- 11.4.2 Modifying Multiple Sequence Alignment for AlphaFold2Based Docking -- 11.5 Conclusion -- 11.5.1 New Models for Binding Affinity Prediction -- 11.5.2 Retrospective from the Compute Industry -- 11.5.2.1 Future DLBased Binding Affinity Computation will Require Massive Scalability. 11.5.2.2 Single GPU Optimizations for DL.

Sommario/riassunto

The book 'Computational Drug Discovery Methods and Applications' edited by Poongavanam and Vijayan Ramaswamy, provides a comprehensive overview of cutting-edge computational techniques in drug discovery. It covers a wide range of topics, including molecular dynamics, quantum mechanics, artificial intelligence, and more. The book is structured into thematic sections focusing on methods such as binding free energy calculations, solvation models, AI-based protein structure predictions, and virtual screening techniques. It aims to equip medicinal and computational chemists, as well as drug discovery professionals, with advanced knowledge and practical insights into the integration of computational tools in drug discovery processes. With contributions from experts in academia and industry, this volume serves as a valuable resource for understanding both theoretical and practical aspects of computational drug design.
